Breaking News Instant updates and real-time market news.

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

13:34
05/24/19
05/24
13:34
05/24/19
13:34

Alpine Immune Sciences Kite pact termination 'a win,' says Piper Jaffray

Last week's new collaboration and license agreement between Alpine Immune Sciences (ALPN) with Adaptimmune (ADAP) essentially replaced the old deal between Kite Pharma and Gilead (GILD), termination of which was announced in a regulatory filing earlier today and is driving Alpine shares lower, Piper Jaffray analyst Edward Tenthoff tells investors in a research note to investors. Tenthoff says he sees this as a win for Alpine, who received $2M upfront and is eligible for an additional $288M in milestones, adding that he is a buyer of Alpine Immune Sciences on today's weakness ahead of ALPN-101 safety and biomarker data this quarter. Tenthoff maintains an Overweight rating and $11 price target on Alpine Immune Sciences shares.

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

GILD

Gilead

$66.88

-0.27 (-0.40%)

  • 31

    May

  • 13

    Jun

  • 17

    Jun

ALPN Alpine Immune Sciences
$5.27

-0.34 (-6.06%)

05/15/19
PIPR
05/15/19
NO CHANGE
Target $11
PIPR
Overweight
Piper sees broad partnership potential for Alpine after Adaptimmune deal
After Alpine Immune Sciences (ALPN) announced a partnership with Adaptimmune (ADAP) to incorporate its novel Transmembrane and Secreted Immunomodulatory Proteins, or TIPs and SIPs, into CAR-T cells, Piper Jaffray analyst Edward Tenthoff said he sees Alpine having broad potential to partner its TIPs and SIPs for next generation cellular therapies. The analyst, who noted that Alpine is also advancing a platform of novel variant Ig domains, or "vIgDs," to augment T-cell activation, keeps an Overweight rating and $11 price target on Alpine shares.
11/11/18
PIPR
11/11/18
NO CHANGE
Target $12
PIPR
Overweight
Piper Jaffray bullish on Alpine after 'robust' ALPN-202 preclinical activity
Piper Jaffray analyst Edward Tenthoff notes that Alpine Immune Sciences presented two posters at SITC for immuno-oncology variable Immunoglobulin Domain candidates. The analyst points out that new preclinical data on ALPN-202, which co-engages PD-L1 and CTLA-4 to selectively stimulates CD28 on T-cells, demonstrated "robust" anti-tumor activity in vivo compared to single agent anti-PD-1 durvalumab. He believes SITC data indicated vIgDs unique co-engagement at the synpase generates superior anti-tumor activity, and says Alpine will file an IND on lead autoimmune vIgD ALPN-101 by year-end 2018 and could prove superior to Orencia with preclinical data at ASH. Tenthoff reiterates an Overweight rating and $12 price target on the shares.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $12
PIPR
Overweight
Alpine Immune Sciences' ALPN-101 active in GvHD, CTA by YE18, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Alpine (ALPN) presented two posters at ASH on proprietary variable Immunoglobulin Domain technology. In vivo data at ASH showed single doses enhanced survival in GvHD models compared to Bristol Myer's (BMY) Nujolix, he notes, adding that a CTA for ALPN-101 by YE18 should enable healthy volunteer data and lead to a Phase II GvHD start next year. The analyst also points out that Alpine presented novel Transmembrane ImmuneModulatory Proteins that can be engineered into T cells to enhance response in immunosuppressive environments. Importantly these strategies differ from TIP technology partnered to Kite (GILD) and offer further partnering opportunity, Tenthoff contends. He reiterates an Overweight rating and $12 price target on Alpine's shares.
01/22/19
PIPR
01/22/19
NO CHANGE
Target $11
PIPR
Overweight
Alpine Immune Sciences target lowered to $11 placement dilution at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Alpine Immune Sciences to $11 from $12 to reflect dilition from the company's recent private placement. Alpine recently issued 4.7 million units at $5.37 comprised of one share and 0.39 warrants with a $12.74 strike price raising gross proceeds of $25.3M, Tenthoff tells investors in a research note. The analyst estimates Alpine now holds pro forma cash of $86M to advance its pipeline of proprietary variant Ig domains as novel immunotherapies. He reiterates an Overweight rating on the shares.
ADAP Adaptimmune
$3.62

-0.03 (-0.82%)

05/07/19
RAJA
05/07/19
NO CHANGE
Target $6
RAJA
Outperform
Adaptimmune price target lowered to $6 from $16 at Raymond James
Raymond James analyst Reni Benjamin lowered his price target for Adaptimmune to $6 from $16, while reiterating an Outperform rating on the shares after the company presented Q1 financial results and provided a "major update" for the ongoing clinical programs. The analyst notes that preliminary results from synovial sarcoma patients treated at therapeutically relevant doses of ADP-A2M4 showed "promising results," and that the company plans to initiate a Phase 2 SPEARHEAD-1 study of ADP-A2M4 in synovial sarcoma patients in the second half of 2019 and to initiate two additional studies to evaluate efficacy and durability of ADP-A2M4 and ADP-A2M10 with radiation in several solid tumor indications. Outside of synovial sarcoma, all other indications showed promising but mixed results, he added.
12/13/18
RHCO
12/13/18
NO CHANGE
Target $12
RHCO
Buy
Adaptimmune price target lowered to $12 from $18 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Adaptimmune to $12 to reflect the pullback in the Biotech sector ahead of ASH. The analyst keeps his Buy rating on the shares however, claiming that the recent departure of the company CTO Gwen Binder, while a negative surprise, is not a "reflection of the company's transition from preclinical to clinical execution". Lawson further believes that Adaptimmune is insulated from any related to the departure disruption given that its CMO assumed the CTO functions in August.
05/07/19
LEER
05/07/19
DOWNGRADE
LEER
Market Perform
Adaptimmune downgraded to Market Perform from Outperform at SVB Leerink
GILD Gilead
$66.88

-0.27 (-0.40%)

05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.
05/20/19
FBCO
05/20/19
INITIATION
Target $70
FBCO
Neutral
Gilead initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Gilead Sciences with a Neutral rating and $70 price target. The does not see "outsized growth" in the company's base HIV business that would drive significant upside to earnings projections. He admits, however, that a new strategic vision or acquisition could lead to multiplier expansion.
05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Gilead upgraded to Buy from Neutral at Citi
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."

TODAY'S FREE FLY STORIES

KRYS

Krystal Biotech

$41.15

11.87 (40.54%)

07:30
06/25/19
06/25
07:30
06/25/19
07:30
Recommendations
Krystal Biotech analyst commentary  »

Krystal Biotech price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

ETFC

E-Trade

$44.57

-1.66 (-3.59%)

07:30
06/25/19
06/25
07:30
06/25/19
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

ALDX

Aldeyra

$7.08

-0.29 (-3.93%)

07:30
06/25/19
06/25
07:30
06/25/19
07:30
Hot Stocks
Breaking Hot Stocks news story on Aldeyra 

Aldeyra trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$30.51

-0.98 (-3.11%)

07:26
06/25/19
06/25
07:26
06/25/19
07:26
Periodicals
Buffett denies reports of tension between him, 3G over Kraft Heinz, CNBC reports »

Buffett says 3G's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$223.66

1.76 (0.79%)

07:26
06/25/19
06/25
07:26
06/25/19
07:26
Recommendations
Tesla analyst commentary  »

Oppenheimer continues to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$72.05

0.91 (1.28%)

, MCD

McDonald's

$203.92

-0.29 (-0.14%)

07:26
06/25/19
06/25
07:26
06/25/19
07:26
Upgrade
GrubHub, McDonald's, Starbucks rating change  »

Citi sees five reasons to…

GRUB

GrubHub

$72.05

0.91 (1.28%)

MCD

McDonald's

$203.92

-0.29 (-0.14%)

SBUX

Starbucks

$83.65

-0.16 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 26

    Jul

ERI

Eldorado Resorts

$45.86

-5.36 (-10.46%)

07:25
06/25/19
06/25
07:25
06/25/19
07:25
Conference/Events
Eldorado Resorts to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

BPOP

Popular

$52.70

0.37 (0.71%)

07:23
06/25/19
06/25
07:23
06/25/19
07:23
Recommendations
Popular analyst commentary  »

Popular's valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

MYGN

Myriad Genetics

$23.04

-0.47 (-2.00%)

07:23
06/25/19
06/25
07:23
06/25/19
07:23
Hot Stocks
Myriad Genetics announces publication of EndoPredict cost effectiveness study »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 06

    Aug

  • 13

    Nov

HEXO

HEXO Corp

$5.35

-0.245 (-4.38%)

07:20
06/25/19
06/25
07:20
06/25/19
07:20
Downgrade
HEXO Corp rating change  »

HEXO Corp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVXL

Anavex

$3.25

-0.12 (-3.56%)

07:20
06/25/19
06/25
07:20
06/25/19
07:20
Hot Stocks
Anavex announces first patient dosed in Rett syndrome extension study »

Anavex announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANGI

Angi Homeservices

$14.38

-0.21 (-1.44%)

07:19
06/25/19
06/25
07:19
06/25/19
07:19
Recommendations
Angi Homeservices analyst commentary  »

Angi Homeservices price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

BHF

Brighthouse Financial

$38.10

-0.01 (-0.03%)

07:19
06/25/19
06/25
07:19
06/25/19
07:19
Downgrade
Brighthouse Financial rating change  »

Brighthouse Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGTC

Applied Genetic

$3.80

-0.145 (-3.68%)

, AERI

Aerie Pharmaceuticals

$30.21

-0.7 (-2.26%)

07:18
06/25/19
06/25
07:18
06/25/19
07:18
Hot Stocks
Applied Genetic names Theresa Heah CMO, Brian Krex general counsel »

Applied Genetic (AGTC)…

AGTC

Applied Genetic

$3.80

-0.145 (-3.68%)

AERI

Aerie Pharmaceuticals

$30.21

-0.7 (-2.26%)

ALXN

Alexion

$126.92

-5.55 (-4.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 10

    Jul

  • 11

    Jul

  • 31

    Jul

  • 01

    Aug

MCHP

Microchip

$85.16

0.08 (0.09%)

07:16
06/25/19
06/25
07:16
06/25/19
07:16
Initiation
Microchip initiated  »

Microchip initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLAB

Silicon Labs

$96.26

-0.41 (-0.42%)

07:14
06/25/19
06/25
07:14
06/25/19
07:14
Initiation
Silicon Labs initiated  »

Silicon Labs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNC

Lincoln National

07:14
06/25/19
06/25
07:14
06/25/19
07:14
Upgrade
Lincoln National rating change  »

Lincoln National upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

TRI

Thomson Reuters

$65.83

-0.16 (-0.24%)

07:13
06/25/19
06/25
07:13
06/25/19
07:13
Downgrade
Thomson Reuters rating change  »

Thomson Reuters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHVN

Biohaven Pharmaceutical

$39.80

-1.26 (-3.07%)

07:13
06/25/19
06/25
07:13
06/25/19
07:13
Recommendations
Biohaven Pharmaceutical analyst commentary  »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

SHW

Sherwin-Williams

$465.88

0.225 (0.05%)

07:13
06/25/19
06/25
07:13
06/25/19
07:13
Downgrade
Sherwin-Williams rating change  »

Sherwin-Williams…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

ARVN

Arvinas

$21.81

(0.00%)

07:12
06/25/19
06/25
07:12
06/25/19
07:12
Hot Stocks
Arvinas announces FDA clearance of ARV-471 IND »

Arvinas announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIF

Tiffany

$91.86

-1.78 (-1.90%)

07:11
06/25/19
06/25
07:11
06/25/19
07:11
Downgrade
Tiffany rating change  »

Tiffany SSS may prove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:10
06/25/19
06/25
07:10
06/25/19
07:10
General news
FX Update: The dollar printed fresh lows »

FX Update: The dollar…

FDS

FactSet

$293.20

-4.89 (-1.64%)

07:10
06/25/19
06/25
07:10
06/25/19
07:10
Hot Stocks
FactSet increases share repurchase program by $210M »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

ABBV

AbbVie

$78.41

-0.37 (-0.47%)

, AGN

Allergan

$129.65

-1.32 (-1.01%)

07:09
06/25/19
06/25
07:09
06/25/19
07:09
Conference/Events
AbbVie to host conference call »

Conference call to…

ABBV

AbbVie

$78.41

-0.37 (-0.47%)

AGN

Allergan

$129.65

-1.32 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.